Dutton Associates Announces Investment Opinion: Avigen Speculative Buy Rating in Initiating Coverage by Dutton Associates
June 12 2006 - 12:05PM
Business Wire
Dutton Associates initiates coverage of Avigen (Nasdaq:AVGN) with a
speculative buy rating and a $8.00 target price. The 12-page report
by Dutton senior analyst William R. Prather, R.Ph., M.D. is
available at www.jmdutton.com as well as from First Call,
Bloomberg, Zacks, Reuters, Knobias, and other leading financial
portals. Avigen is an early-stage biopharmaceutical company whose
business strategy to date has been unique. The Company has licensed
or otherwise patented compounds that already have a clinical track
record. The Company's lead products, AV650 (tolperisone) and AV411
(ibudilast), have seen significant commercial experience
internationally and we believe their safety profile is already
established. Avigen embarked upon a new business strategy of
focusing on therapeutics for neurological and neuromuscular
disorders beginning in 2005. Because the Company is relatively
early in exercising this new business strategy, we believe Avigen's
market value will rise over the near term based on milestone
announcements surrounding the Company's product portfolio.
Additionally, we also compared Avigen with other early-stage
companies involved in Phase I clinical trials, realizing that
Avigen's value should be enhanced because of the assumed safety of
AV650 and AV411 relative to their extensive clinical use
internationally. Based on upcoming milestone announcements and
comparing the current value of Avigen to other early-stage
companies involved in Phase I clinical trials with their respective
lead products, we have assigned a 12-month price target on the
common stock of $8.00 and an investment rating of Speculative Buy.
About Dutton Associates Dutton Associates is one of the largest
independent investment research firms in the U.S. Its 31 senior
analysts are primarily CFAs and have expertise in many industries.
Dutton Associates provides continuing analyst coverage of over 140
enrolled companies, and its research, estimates, and ratings are
carried in all the major databases serving institutions and online
investors. The cost of enrollment in our one-year continuing
research program is US $35,000 prepaid for 4 Research Reports,
typically published quarterly, and requisite Research Notes. Dutton
Associates received $35,000 from the Company for 4 Research Reports
with coverage commencing on 6/12/2006. We do not accept payment of
our fees in company stock. Our principals and analysts are
prohibited from owning or trading in securities of covered
companies. The views expressed in this research report accurately
reflect the analyst's personal views about the subject securities
or issuer. Neither the analyst's compensation nor the compensation
received by us is in any way related to the specific ratings or
views contained in this research report or note. Please read full
disclosures and analyst background at www.jmdutton.com before
investing.
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From May 2024 to Jun 2024
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jun 2023 to Jun 2024